Avelo secures CHF 1.5 Million boost from Innosuisse to revolutionize lower respiratory tract infection diagnosis
14.12.2023
The Innosuisse Grant will allow the startup to drive the development of AveloCollect, a new breath-sampling device aimed at improving the diagnosis of lower respiratory tract infections (LRTIs).
 Avelo's team
|
 |
Lower Respiratory Tract Infections (LRTIs), presently ranking as the fourth leading global cause of death, present a significant challenge to worldwide public health. The accurate identification of pathogens is paramount for selecting targeted treatments and preventing fatalities. Unfortunately, existing sampling methods have shortcomings—either missing lower tract pathogens, resulting in low diagnostic accuracy, or proving highly invasive, leaving up to 50% of patients without a precise diagnosis.
Avelo is committed to addressing this critical issue through the development of AveloCollect, streamlining the collection process for LRTI pathogens by introducing a non-invasive breath-sampling approach. This 34-month project, building upon Avelo's ongoing Eurostars initiative, will center on the clinical development and market readiness of AveloCollect. The device's versatility in detecting various respiratory pathogens positions it as a potential game-changer for introduction into European markets, presenting opportunities for extensive global commercial partnerships.
"The Innosuisse project offers a great opportunity for us to progress along our path to the market. Venture Kick has been instrumental in supporting this exciting journey, playing a key role at the very beginning," said Melanie Aregger, CEO and Co-Founder of Avelo.
Avelo was ranked among the TOP 100 Swiss Startups in 2023 and won the last stage of Venture Kick in 2022.
Avelo's team: Katie Tiseo (Scientist), Martina Moser (Senior Engineer), Tobias Broger (CTO & Co-Founder), Melanie Aregger (CEO & Co-Founder), Xuan Zhou (Researcher), Patricia Risch (Scientist), and Giada Ingoglia (Scientist)
Avelo is committed to addressing this critical issue through the development of AveloCollect, streamlining the collection process for LRTI pathogens by introducing a non-invasive breath-sampling approach. This 34-month project, building upon Avelo's ongoing Eurostars initiative, will center on the clinical development and market readiness of AveloCollect. The device's versatility in detecting various respiratory pathogens positions it as a potential game-changer for introduction into European markets, presenting opportunities for extensive global commercial partnerships.
"The Innosuisse project offers a great opportunity for us to progress along our path to the market. Venture Kick has been instrumental in supporting this exciting journey, playing a key role at the very beginning," said Melanie Aregger, CEO and Co-Founder of Avelo.
Avelo was ranked among the TOP 100 Swiss Startups in 2023 and won the last stage of Venture Kick in 2022.
Avelo's team: Katie Tiseo (Scientist), Martina Moser (Senior Engineer), Tobias Broger (CTO & Co-Founder), Melanie Aregger (CEO & Co-Founder), Xuan Zhou (Researcher), Patricia Risch (Scientist), and Giada Ingoglia (Scientist)